短暂靶向调节性T细胞可触发多发性骨髓瘤免疫控制并阻止疾病进展
该临床前研究利用两种遗传背景的同基因免疫健全小鼠多发性骨髓瘤模型,分析骨髓Treg的空间免疫分布及其功能。结果显示骨髓Treg聚集于恶性浆细胞附近并呈活化表型,体内清除Treg可阻止多发性骨髓瘤播散;对已建立多发性骨髓瘤的小鼠进行短期Treg清除,可引发CD8 T细胞和NK细胞介导的强效免疫应答,实现完全且稳定的缓解。
要点
- 骨髓Treg聚集于恶性浆细胞附近并呈活化表型,为骨髓瘤提供免疫保护微环境。
- 体内清除Treg可在两种小鼠模型中阻止多发性骨髓瘤播散。
- 对已建立疾病的小鼠短期清除Treg可诱导CD8 T细胞和NK细胞介导的完全稳定缓解。
核心结论
- 临床前体内研究提示Treg是多发性骨髓瘤治疗的有吸引力靶点,短暂靶向Treg可触发免疫控制并阻止疾病进展。
研究设计与样本
- 研究采用两种不同遗传背景的同基因免疫健全小鼠多发性骨髓瘤模型,进行空间免疫结构分析与体内Treg清除实验。
主要发现
- 骨髓Treg在恶性浆细胞附近聚集并显示活化表型。
- 体内Treg清除在两种模型中均阻止多发性骨髓瘤播散。
- 对已建立多发性骨髓瘤的小鼠短期体内清除Treg,引发强效CD8 T细胞和NK细胞介导的免疫应答,导致完全且稳定的缓解。
临床怎么用
- 提示Treg清除策略可能作为多发性骨髓瘤的免疫治疗方向,尚需临床研究验证。
局限性
- 证据来自小鼠临床前模型,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma remains a largely incurable disease of clonally expanding malignant plasma cells. The bone marrow microenvironment harbors treatment-resistant myeloma cells, which eventually lead to disease relapse in patients. In the bone marrow, CD4+FoxP3+ regulatory T cells (Tregs) are highly abundant amongst CD4+ T cells providing an immune protective niche for different long-living cell populations, e.g., hematopoietic stem cells. Here, we addressed the functional role of Tregs in multiple myeloma dissemination to bone marrow compartments and disease progression. To investigate the immune regulation of multiple myeloma, we utilized syngeneic immunocompetent murine multiple myeloma models in two different genetic backgrounds. Analyzing the spatial immune architecture of multiple myeloma revealed that the bone marrow Tregs accumulated in the vicinity of malignant plasma cells and displayed an activated phenotype. In vivo Treg depletion prevented multiple myeloma dissemination in both models. Importantly, short-term in vivo depletion of Tregs in mice with established multiple myeloma evoked a potent CD8 T cell- and NK cell-mediated immune response resulting in complete and stable remission. Conclusively, this preclinical in-vivo study suggests that Tregs are an attractive target for the treatment of multiple myeloma.
引用
- Dahlhoff J, Manz H, Steinfatt T, et al. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia. 2021. PMID: 34584204. doi:10.1038/s41375-021-01422-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。